ORCHID PHARMA
PharmaORCHID PHARMA is a pharmaceutical company focused on Infectious Disease. Key products include EXBLIFEP.
FDA Novel Drug Designations
(2024)See 1 novel approval →
ORCHID PHARMA's Key Drugs
ORCHID PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ORCHID PHARMA's Recent FDA Approvals
New NDA/BLA approvals for ORCHID PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
ORCHID PHARMA's Therapeutic Areas
ORCHID PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ORCHID PHARMA's Top Competitors
ORCHID PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ORCHID PHARMA Pipeline Snapshot
ORCHID PHARMA has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 2024-02-22
- Latest
- 2024-02-22
- Applications
- 1